Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.77 |
| ▸ | BRAF | P15056 | 2/20 | 0.77 |
| ▸ | KDR | P35968 | 9/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787911 | 1.00 | RAF1 (0.77) | RAF1BRAFKDRPDGFRBFLT3 | |
| SCHEMBL1791731 | 0.84 | BRAF (0.62) | RAF1BRAFKDRPDGFRBFLT3 | |
| SCHEMBL1791767 | 0.83 | RAF1 (0.63) | RAF1BRAFKDRFLT3 | |
| SCHEMBL1789941 | 0.83 | RAB9A (0.63) | RAF1BRAFKDRPDGFRBFLT3 | |
| SCHEMBL1790198 | 0.82 | RAF1 (0.69) | RAF1BRAFKDRFLT3 | |
| SCHEMBL1791695 | 0.82 | RAF1 (0.61) | RAF1BRAFKDRFLT3 | |
| SCHEMBL18615348 | 0.80 | KDR (0.85) | KDRAURKBTRPV1CA1CA2 | |
| SCHEMBL5523848 | 0.78 | RAF1 (0.52) | RAF1BRAFKDRPDGFRBFLT3 | |
| SCHEMBL25482048 | 0.77 | KDR (0.82) | RAF1BRAFKDRPDGFRBAURKB | |
| SCHEMBL118026 | 0.76 | KDR (1.00) | KDRTRPV1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-1797072-A4 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1797072-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033943-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | RAF1 60/4885BRAF 36/4885KDR 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.